Overview

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

Status:
Completed

Trial end date:
2020-07-15

Target enrollment:

Participant gender:

Summary

This study will be conducted to assess the pharmacokinetics of vadadustat 600, 750, and 900 milligrams daily, and intravenous erythropoiesis-stimulating agent (darbepoetin alfa or epoetin alfa), in hemodialysis participants with anemia associated with chronic kidney disease.

Phase:

Phase 1

Details

Lead Sponsor:

Akebia Therapeutics

Treatments:

Darbepoetin alfa
Epoetin Alfa
Glycine
Hematinics